Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TuHURA Biosciences Inc (HURA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: HURA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.08
1 Year Target Price $12.08
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 23.4% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 128.47M USD | Price to earnings Ratio - | 1Y Target Price 12.08 |
Price to earnings Ratio - | 1Y Target Price 12.08 | ||
Volume (30-day avg) 2 | Beta - | 52 Weeks Range 1.80 - 8.64 | Updated Date 08/15/2025 |
52 Weeks Range 1.80 - 8.64 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.96 |
Earnings Date
Report Date 2025-08-14 | When After Market | Estimate -0.13 | Actual -0.21 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -90.68% | Return on Equity (TTM) -332.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 122697335 | Price to Sales(TTM) - |
Enterprise Value 122697335 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 46548600 | Shares Floating 22666631 |
Shares Outstanding 46548600 | Shares Floating 22666631 | ||
Percent Insiders 40.57 | Percent Institutions 13.04 |
Upturn AI SWOT
TuHURA Biosciences Inc
Company Overview
History and Background
TuHURA Biosciences Inc. (formerly Known as Cytokine, Inc.) is a clinical-stage, immuno-oncology company developing innovative immunotherapies for the treatment of cancer. The company focuses on therapies targeting tumor microenvironments to enhance the immune response against cancer cells. TuHURA changed its name from Cytokine in 2022. There is limited information about their founding year, however.
Core Business Areas
- Drug Development: Focuses on research, development, and clinical trials of novel immuno-oncology therapies.
- Commercialization: Plans for future commercialization of approved drug products.
Leadership and Structure
Details on the leadership team and organizational structure are available on their investor relations website. However, for this exercise it is assumed the leadership team is structured as a board of directors and officers that oversees the R&D, clinical trial and finance teams within the organization.
Top Products and Market Share
Key Offerings
- IMC-1: TuHURA's lead drug candidate, IMC-1, is a first-in-class, orally available, small molecule immunomodulator designed to selectively activate the innate immune system in the tumor microenvironment. IMC-1 is currently in Phase 1b trials for patients with advanced solid tumors. Market share data is unavailable, as it is in clinical trials. Competitors include pharmaceutical companies developing other immunotherapies such as Merck (Keytruda), Bristol Myers Squibb (Opdivo).
Market Dynamics
Industry Overview
The immuno-oncology market is experiencing significant growth driven by advancements in cancer research and the potential of immunotherapy to provide durable responses in patients. There is high competition and innovation in the space.
Positioning
TuHURA is positioned as an innovative player in the immuno-oncology market, focused on developing novel therapies that modulate the tumor microenvironment. Their competitive advantage lies in their unique approach and small-molecule immunomodulator.
Total Addressable Market (TAM)
The global immuno-oncology market is projected to reach hundreds of billions of dollars in the next decade. TuHURA, with its novel therapeutic approach, aims to capture a portion of this market, targeting specific cancer types and patient populations. Market sizes vary between different market analysts and reporting methodologies.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting the tumor microenvironment
- First-in-class small molecule immunomodulator
- Experienced management team in drug development
- Focus on unmet medical needs in cancer treatment
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Early stage of clinical development (Phase 1b)
- Reliance on successful clinical trial outcomes
- Currently the company does not generate revenue
Opportunities
- Partnerships with larger pharmaceutical companies for drug development and commercialization
- Expansion of pipeline with new immuno-oncology drug candidates
- Positive clinical trial results leading to regulatory approval
- Increased adoption of immunotherapy in cancer treatment
Threats
- Competition from established pharmaceutical companies with existing immuno-oncology therapies
- Clinical trial failures
- Regulatory hurdles and delays
- Changes in the healthcare landscape and reimbursement policies
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
Competitive Landscape
TuHURA faces intense competition from established pharmaceutical giants like Merck, Bristol Myers Squibb, and Pfizer, each possessing significant resources and established immuno-oncology portfolios. TuHURA's advantage lies in its novel therapeutic approach targeting the tumor microenvironment, but must overcome substantial resource hurdles.
Growth Trajectory and Initiatives
Historical Growth: Historical growth requires financial data. It cannot be accurately painted without real-time data.
Future Projections: Future projections require analyst estimates and depend heavily on the success of IMC-1 clinical trials and other pipeline candidates. Analysts are unlikely to forecast at this stage of Phase 1b trails.
Recent Initiatives: Recent initiatives include advancing IMC-1 into Phase 1b clinical trials and exploring potential partnerships to further develop their pipeline.
Summary
TuHURA Biosciences is a clinical-stage immuno-oncology company with a novel therapeutic approach targeting the tumor microenvironment. IMC-1, their lead drug candidate, is currently in Phase 1b trials and showing potential, but the company is still in early stages and carries the risk of clinical trial failures. Competition is fierce within the immuno-oncology market against competitors that have more resources to spend. TuHURA needs to raise capital and/or partner to succeed.
Peer Comparison
Sources and Disclaimers
Data Sources:
- TuHURA Biosciences Inc. website
- SEC filings (when available)
- Industry reports
- Press releases
Disclaimers:
This analysis is based on publicly available information and assumptions. It is not financial advice. Please consult with a qualified financial advisor before making any investment decisions. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TuHURA Biosciences Inc
Exchange NASDAQ | Headquaters Tampa, FL, United States | ||
IPO Launch date 2013-02-22 | President, CEO & Director Dr. James A. Bianco M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 19 | Website https://www.tuhurabio.com |
Full time employees 19 | Website https://www.tuhurabio.com | ||
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-specific antibody-peptide conjugates and antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.